Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15000480 | 0.89 | NFE2L2 (0.56) | NFE2L2TDP1MEN1KMT2A | |
| SCHEMBL15000389 | 0.86 | NFE2L2 (0.66) | NFE2L2MEN1KMT2A | |
| SCHEMBL14725174 | 0.84 | NFE2L2 (0.69) | NFE2L2MEN1KMT2A | |
| SCHEMBL10223303 | 0.84 | TDP1 (0.67) | TDP1ITGB3ITGA2BKDM1ASLC6A2 | |
| SCHEMBL16638703 | 0.83 | KDM4E (0.50) | ITGB3ITGA2BMEN1KMT2ASLC6A2 | |
| SCHEMBL15651091 | 0.83 | NFE2L2 (0.71) | NFE2L2TDP1ITGB3ITGA2BADORA3 | |
| SCHEMBL13144645 | 0.83 | TDP1 (0.51) | NFE2L2TDP1ITGB3ITGA2BKDM1A | |
| SCHEMBL4326032 | 0.83 | NPY1R (0.50) | NFE2L2TDP1ITGB3ITGA2BADORA3 | |
| SCHEMBL13335378 | 0.83 | ITGB3 (0.52) | NFE2L2TDP1ITGB3ITGA2BADORA3 | |
| SCHEMBL13761598 | 0.80 | TDP1 (0.49) | NFE2L2TDP1ITGB3ITGA2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ABS DEVELOPMENT 1, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10647720-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | Asan BioSciences, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190092779-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | Libertas Bio, Inc. | 2019-03-28 | — | — | US | disclosed |
| US-20190070182-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC | 2019-03-07 | — | — | US | disclosed |
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | ASANA BIOSCIENCES, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | THPO, TYMP, TYMS | NFE2L2 2209/4885TDP1 2246/4885ITGB3 1915/4885 |
| US-20190070182-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | NFE2L2 3155/4885TDP1 2009/4885ITGB3 2037/4885 |
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | MKI67, DPYD, TYMP | NFE2L2 3155/4885TDP1 2009/4885ITGB3 2037/4885 |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | NFE2L2 3155/4885TDP1 2009/4885ITGB3 2037/4885 |
| US-20190092779-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | NFE2L2 2209/4885TDP1 2246/4885ITGB3 1915/4885 |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | NFE2L2 2209/4885TDP1 2246/4885ITGB3 1915/4885 |
| US-10647720-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | THPO, TYMP, TYMS | NFE2L2 2209/4885TDP1 2246/4885ITGB3 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.